Buyout Desk
Investment

Biospring Partners leads growth investment in Serán Bioscience

The capital will help the Bend, Oregon-based contract development and manufacturing organization move from clinical-stage manufacturing into commercial production, with emphasis on particle engineering and spray drying.

Target
Serán Bioscience
Investor
Biospring Partners

Serán Bioscience, a contract development and manufacturing organization for pharmaceutical and biotechnology companies, has secured growth capital led by Biospring Partners. The investment supports Serán’s expansion from clinical-stage manufacturing into commercial production, with emphasis on particle engineering and spray drying.

“This investment is a significant milestone in Serán’s evolution as we rapidly scale our clinical manufacturing operations to support launches of new medicines, as well as serve new clients seeking a state-of-the-art commercial manufacturing partner,” said Dan Smithey, co-founder and CEO of Serán. Existing investors Vivo Capital and Bain Capital Life Sciences participated in the round.

Background

Deal type
Investment
Headquarters
Bend, OR

Sources

Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.